Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LFnp24B.C therapeutic HIV vaccine in ART-treated adults with incomplete immune reconstitution
ChiCTR2100042269Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2020
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LFn-p24B.C in human immunodeficiency virus infection (HIV) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Safety and Immune reconstitution. Started Sep 2020; status: recruiting.
02
Drugs
LFn-p24B.C
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2100042269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042269.